Mirum Pharmaceuticals (MIRM) Preferred Stock Liabilities (2018 - 2019)
Mirum Pharmaceuticals' quarterly Preferred Stock Liabilities came in at $7.0 million in Q2 2019, down 88.32% quarter-over-quarter from $59.8 million in Q1 2019.
Mirum Pharmaceuticals has reported Preferred Stock Liabilities for 2 years, with the latest figure at $7.0 million in Q2 2019.
- For the quarter ending Q2 2019, Preferred Stock Liabilities changed N/A year-over-year to $7.0 million; the trailing twelve-month figure through Jun 2019 stood at $7.0 million (changed N/A YoY), and the FY2018 full-year result was $7.0 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q2 2019 stood at $7.0 million, down from $59.8 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $59.8 million in Q1 2019, with the low at $7.0 million in Q4 2018.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Mirum Pharmaceuticals | 5.97 Bn | 5.59 Bn | 131.08 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2019 | 6.99 Mn |
| Mar 31, 2019 | 59.85 Mn |
| Dec 31, 2018 | 6.99 Mn |